In our clinic, all women were treated with a long agonist protocol starting from oral contraceptives (OCs) (Ovulastan, Adamed, Czosnow, Poland) from day 2–5 of the cycle. Triptorelin acetate 0.1 mg (Gonapeptyl, Ferring, Saint-Prex, Switzerland) was administered 14 days after the beginning of the OCs. Fourteen days later (seven days after the end of OC administration), urinary gonadotropins (Menopur, Ferring, Saint-Prex, Switzerland) for ovarian stimulation were administered. The dosage administered was dependent on AMH level, and ranged from 150 to 300 IU daily (12). Follicular growth was monitored on stimulation day 8 using transvaginal ultrasound and assays evaluating serum estradiol (E2), progesterone (P), and luteinizing hormone (LH) levels. Oocyte pick-up was performed 36 h after the administration of 5000 IU of hCG (Choragon, Ferring, Saint-Prex, Switzerland).
Choragon
Manufactured by Ferring
Sourced in Switzerland
Choragon is a product used in laboratory settings. It contains the active ingredient human chorionic gonadotropin (hCG), a hormone that plays a role in various biological processes. The core function of Choragon is to serve as a reagent for in vitro diagnostic applications, but a detailed description of its intended use or applications cannot be provided in an unbiased and factual manner within the given constraints.
Automatically generated - may contain errors
Lab products found in correlation
4 protocols using choragon
1
Long Agonist Protocol for IVF
2
Controlled Ovarian Stimulation Protocols
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Each patient accepted a controlled ovarian stimulation (COS) regimen such as long, ultralong, and microstimulation protocol according to their ovarian function and responses during previous IVF cycles or ovulation induction. The diameter of follicles was monitored every 2-3 days, and ovulation was induced with human chorionic gonadotropin (hCG; Choragon, Ferring, Switzerland, 5000-10,000 IU) alone or in combination with triptorelin acetate (Ferring, 0.2 mg) when at least two leading follicles grew up to 18 mm.
3
Ovarian Stimulation Protocols for IVF
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Different COS regimens, i.e. long, antagonist and others (minimal stimulation, natural, luteal phase stimulation and progestinprimed stimulation), were selected for ovarian stimulation according to patients' characteristics and responses during previous IVF cycles or ovulation induction. When the diameter of at least one leading follicle was 18 mm, ovulation was induced with 5000-10,000 IU of human chorionic gonadotropin (hCG; Choragon, Ferring, Switzerland), alone or in combination with 0.2 mg triptorelin acetate (Ferring). Transvaginal ultrasound-guided oocyte retrieval was performed at 36 h after hCG administration.
4
Ovarian Stimulation Protocol for IVF
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All women were treated on a long agonist protocol starting with oral contraceptive pills (Ovulastan, Adamed) taken on days 2-5 of the cycle. Triptorelin acetate 0.1 mg (Gonapeptyl, Ferring Pharmaceuticals) was administered 14 days after patients began taking the contraceptive. Fourteen days later (7 days after the oral contraceptive was stopped), the administration of urinary gonadotropins (Menopur, Ferring Pharmaceuticals) for ovarian stimulation was initiated; the dosage was dependent on the anti-M€ ullerian hormone level (150-300 international units [IU] daily) (18) .
Monitoring of follicular growth was carried out on day 8 by ultrasonographic scan and assays of serum estradiol (E 2 ), progesterone (P), and luteinizing hormone (LH). Oocyte pickup was performed 36 hours after the administration of 5,000 IU of human chorionic gonadotropin hCG (Choragon, Ferring Pharmaceuticals). The luteal phase was supplemented by transvaginal P (100 mg, three times a day; Lutinus, Ferring Pharmaceuticals) and E 2 (2 mg, three times a day vaginally; Estrofem NovoNordisk); hormone levels (E 2 , P, and hCG) were checked every 3 to 4 days.
Monitoring of follicular growth was carried out on day 8 by ultrasonographic scan and assays of serum estradiol (E 2 ), progesterone (P), and luteinizing hormone (LH). Oocyte pickup was performed 36 hours after the administration of 5,000 IU of human chorionic gonadotropin hCG (Choragon, Ferring Pharmaceuticals). The luteal phase was supplemented by transvaginal P (100 mg, three times a day; Lutinus, Ferring Pharmaceuticals) and E 2 (2 mg, three times a day vaginally; Estrofem NovoNordisk); hormone levels (E 2 , P, and hCG) were checked every 3 to 4 days.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!